Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study.

摘要: Aliment Pharmacol Ther 2010; 32: 377–383 Summary Background  Vitamin D has immune-regulatory functions in experimental colitis, and low vitamin levels are present Crohn’s disease. Aim  To assess the effectiveness of D3 treatment disease with regard to improved course. Methods  We performed a randomized double-blind placebo-controlled trial benefits oral disease. included 108 patients remission, which fourteen were excluded later. Patients receive either 1200 IU (n = 46) or placebo (n = 48) once daily during 12 months. The primary endpoint was clinical relapse. Results  Oral increased serum 25OHD from mean 69 nmol/L [standard deviation (s.d.) 31 nmol/L] 96 nmol/L (s.d. 27 nmol/L) after 3 months (P < 0.001). relapse rate lower among treated (6/46 13%) than (14/48 29%), (P = 0.06). Conclusions  supplementation 1200 IE significantly insignificantly reduced risk 29% 13%, (P = 0.06). Given that might be effective disease, we suggest larger studies elucidate this matter further. ClinicalTrial.gov(NCT00122184).